WO2005027874A3 - Solid or semi-solid therapeutic formulations - Google Patents

Solid or semi-solid therapeutic formulations Download PDF

Info

Publication number
WO2005027874A3
WO2005027874A3 PCT/US2004/030292 US2004030292W WO2005027874A3 WO 2005027874 A3 WO2005027874 A3 WO 2005027874A3 US 2004030292 W US2004030292 W US 2004030292W WO 2005027874 A3 WO2005027874 A3 WO 2005027874A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid
dosage form
semi
therapeutic formulations
injectable
Prior art date
Application number
PCT/US2004/030292
Other languages
French (fr)
Other versions
WO2005027874A2 (en
Inventor
Weenna Bucay-Couto
Sheng-Ping Zhong
Arthur Madenjian
Enxin Ma
Barry N Gellman
Original Assignee
Scimed Life Systems Inc
Weenna Bucay-Couto
Sheng-Ping Zhong
Arthur Madenjian
Enxin Ma
Barry N Gellman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scimed Life Systems Inc, Weenna Bucay-Couto, Sheng-Ping Zhong, Arthur Madenjian, Enxin Ma, Barry N Gellman filed Critical Scimed Life Systems Inc
Priority to EP04784227A priority Critical patent/EP1663143A2/en
Publication of WO2005027874A2 publication Critical patent/WO2005027874A2/en
Publication of WO2005027874A3 publication Critical patent/WO2005027874A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

An injectable or insertable dosage form comprising a biodisintegrable binder and an ablation agent in a concentration effective to cause tissue necrosis. The injectable dosage form is a solid or semi-solid dosage form. Due to the solid or semi-solid nature of the dosage form, retention at the site of injection or insertion is improved, thereby improving delivery efficiency of the ablation agents within the dosage form and/or reducing the nonspecific tissue damage associated with the dosage form.
PCT/US2004/030292 2003-09-18 2004-09-15 Solid or semi-solid therapeutic formulations WO2005027874A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04784227A EP1663143A2 (en) 2003-09-18 2004-09-15 Solid or semi-solid therapeutic formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/664,601 2003-09-18
US10/664,601 US7906125B2 (en) 2003-09-18 2003-09-18 Solid or semi-solid therapeutic formulations

Publications (2)

Publication Number Publication Date
WO2005027874A2 WO2005027874A2 (en) 2005-03-31
WO2005027874A3 true WO2005027874A3 (en) 2006-01-05

Family

ID=34312780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/030292 WO2005027874A2 (en) 2003-09-18 2004-09-15 Solid or semi-solid therapeutic formulations

Country Status (3)

Country Link
US (1) US7906125B2 (en)
EP (1) EP1663143A2 (en)
WO (1) WO2005027874A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
ATE405352T1 (en) 2000-05-16 2008-09-15 Univ Minnesota PARTICLE GENERATION FOR HIGH MASS THROUGHPUT WITH A MULTIPLE NOZZLE ARRANGEMENT
US7247338B2 (en) * 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
US8920826B2 (en) * 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
US8263109B2 (en) * 2005-05-09 2012-09-11 Boston Scientific Scimed, Inc. Injectable bulking compositions
US7806871B2 (en) 2005-05-09 2010-10-05 Boston Scientific Scimed, Inc. Method and device for tissue removal and for delivery of a therapeutic agent or bulking agent
US7862552B2 (en) * 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
CN1962155A (en) * 2005-11-10 2007-05-16 鸿富锦精密工业（深圳）有限公司 CO2 laser welding apparatus
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
CA2637883C (en) * 2006-01-31 2015-07-07 Regents Of The University Of Minnesota Electrospray coating of objects
EP2529761B1 (en) * 2006-01-31 2017-06-14 Nanocopoeia, Inc. Nanoparticle coating of surfaces
AU2007226258A1 (en) * 2006-03-10 2007-09-20 Mcgill University Ultrasound molecular sensors and uses thereof
US9040816B2 (en) * 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
ES2703004T3 (en) * 2009-08-19 2019-03-06 Freudenberg Carl Kg Procedure, device for reading a topographic structure placed on a component, and component
JP6359390B2 (en) * 2014-09-05 2018-07-18 テルモ株式会社 Implant device and implant device implant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63150216A (en) * 1986-12-12 1988-06-22 Ichimaru Pharcos Co Ltd Agent for massaging body or gingiva
US20030147936A1 (en) * 2002-02-07 2003-08-07 Velayudhan Sahadevan Prostatic hormonal implants treatment of prostate cancer
WO2004004709A1 (en) * 2002-07-10 2004-01-15 Ashvin Desai Gel injection treatment of body parts

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB811717A (en) 1954-07-28 1959-04-08 Pfizer & Co C Improvements in or relating to therapeutic compositions
US4927806A (en) * 1987-04-23 1990-05-22 The Regents Of The University Of California Saturated salt/concentrated dextran formulation to treat hemorrhage
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5147631A (en) * 1991-04-30 1992-09-15 Du Pont Merck Pharmaceutical Company Porous inorganic ultrasound contrast agents
US7549424B2 (en) * 1991-10-18 2009-06-23 Pro Surg, Inc. Method and apparatus for tissue treatment with laser and electromagnetic radiation
US6231591B1 (en) * 1991-10-18 2001-05-15 2000 Injectx, Inc. Method of localized fluid therapy
US6461296B1 (en) * 1998-06-26 2002-10-08 2000 Injectx, Inc. Method and apparatus for delivery of genes, enzymes and biological agents to tissue cells
US6015541A (en) * 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
UA72189C2 (en) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US6869927B1 (en) * 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CN1068778C (en) 1998-05-15 2001-07-25 赵超英 Novel drug composition for treating and curing and its preparing method
KR100293504B1 (en) * 1998-06-05 2001-07-12 김윤 Sustanined-releasing anti-prostatitic composition and preparing method thereof
WO2000025752A1 (en) * 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
HUP0202880A3 (en) 1999-07-15 2003-04-28 Takeda Chemical Industries Ltd Sustained release compositions, process for producing the same and use thereof
JP2003531682A (en) * 2000-04-28 2003-10-28 フジオメッド インコーポレイテッド Hemostatic compositions of polyacids and polyalkylene oxides and methods of using the same
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
WO2002058578A1 (en) * 2000-11-13 2002-08-01 Wit Ip Corporation Treatment catheters with thermally insulated regions
AU2002322493A1 (en) 2001-07-10 2003-01-29 Ams Research Corporation Surgical kit for treating prostate tissue
EP1434530A2 (en) * 2001-10-12 2004-07-07 AMS Research Corporation Surgical instrument and method
US7226622B2 (en) * 2003-09-18 2007-06-05 Boston Scientific Scimed, Inc. Chemoablation of tissue using biodegradable, solid salt dosage forms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63150216A (en) * 1986-12-12 1988-06-22 Ichimaru Pharcos Co Ltd Agent for massaging body or gingiva
US20030147936A1 (en) * 2002-02-07 2003-08-07 Velayudhan Sahadevan Prostatic hormonal implants treatment of prostate cancer
WO2004004709A1 (en) * 2002-07-10 2004-01-15 Ashvin Desai Gel injection treatment of body parts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LARSON BENJAMIN T ET AL: "Histological changes of minimally invasive procedures for the treatment of benign prostatic hyperplasia and prostate cancer: Clinical implications.", JOURNAL OF UROLOGY, vol. 170, no. 1, July 2003 (2003-07-01), pages 12 - 19, XP002352943, ISSN: 0022-5347 *
PATENT ABSTRACTS OF JAPAN vol. 012, no. 410 (C - 540) 28 October 1988 (1988-10-28) *

Also Published As

Publication number Publication date
US7906125B2 (en) 2011-03-15
WO2005027874A2 (en) 2005-03-31
US20050064008A1 (en) 2005-03-24
EP1663143A2 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
WO2005027874A3 (en) Solid or semi-solid therapeutic formulations
WO2003005889A3 (en) Surgical kit for treating prostate tissue
WO2003063799A3 (en) Compositions and methods for systemic inhibition of cartilage degradation
BR0111800A (en) Depeptidyl peptidase iv inhibitor combinations and other antidiabetic agents for the treatment of diabetes mellitus
WO2001041707A3 (en) Modulation of in vivo glutamine and glycine levels in the treatment of autism
WO2006121518A3 (en) Electrical devices, anti-scarring agents, and therapeutic compositions
WO2006055008A3 (en) Implantable sensors and implantable pumps and anti-scarring agents
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
CY1107649T1 (en) A COMBINATION CONTAINING AN ANTIFOLIC SALT AND Methylphenolic Acid Reduction Factors
WO2006058140A3 (en) Capsaicinoid gel formulation and uses thereof
AU2003274681A8 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
CO5261582A1 (en) VALDECOXIB COMPOSITIONS
WO2007041584A3 (en) Implantable sensors, implantable pumps, and anti-scarring drug combinations
WO1998029105A3 (en) Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations
WO2009004995A1 (en) Method of fixing and expressing physiologically active substance
AR046690A1 (en) COMPOSITIONS OF STABILIZED DNA TO COVER MICROPROJECTIONS
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
ECSP045153A (en) METHOD AND COMPOSITION TO INCREASE THE POWER OF A NARCOTIC ANALGEST.
AU2002211536A1 (en) Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals
GB9903403D0 (en) Substituted stilbene compounds with vascular damaging activity
CO5241299A1 (en) APPLIANCE AND METHOD TO ADMINISTER A MEDICINAL SPRAY
NO20051261L (en) Morphine-6-glukuronidsalt
WO2009088673A3 (en) Pharmaceutical composition
EP1557163A4 (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004784227

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004784227

Country of ref document: EP